The traditional approach for estimating noncancer and cancer reference values in quantitative chemical risk assessment is time and resource intensive. The extent and nature of the studies required under the traditional approach has limited the number of chemicals with published risk assessments. In this study, female mice were exposed for 13 weeks to multiple concentrations of five chemicals that were positive in a 2-year cancer bioassay. Traditional histological and organ weight changes were evaluated, and gene expression microarray analysis was performed on the target tissues. The histological, organ weight changes, and the original tumor incidences in the original cancer bioassay were analyzed using standard benchmark dose (BMD) methods to identify noncancer and cancer points of departure, respectively. The dose-related changes in gene expression were also analyzed using a BMD approach and the responses grouped based on cellular biological processes. A comparison of the transcriptional BMD values with those for the traditional noncancer and cancer apical endpoints showed a high degree of correlation for specific cellular biological processes. For chemicals with human exposure data, the transcriptional BMD values were also used to calculate a margin of exposure. The margins of exposure ranged from 1900 to 54,000. Both the correlation between the BMD values for the transcriptional and apical endpoints and the margin of exposure analysis suggest that transcriptional BMD values may be used as potential points of departure for noncancer and cancer risk assessment.
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The quantitative assessment of health risks associated with chemical exposure is a time and resource intensive process that can require years to complete. For a given chemical, all relevant biochemical, cellular, animal, and human studies are collected and evaluated in the context of the four steps of the risk assessment process. These steps include hazard identification, dose-response assessment, exposure assessment, and risk characterization (National Research Council [NRC], 1983 , 1994 . Upon completion, the results for industrial and environmental chemicals are published by groups such as the U.S. Environmental Protection Agency's (U.S. EPA) Integrated Risk Information System (IRIS) Program or by the Office of Pesticides Programs for pesticide chemicals. If a chemical does not have adequate data, no risk assessment values are published. Given the fact that there are thousands of chemicals currently in use with health assessment information only available on a small number of them, there is a need for defining ways to use more easily obtainable information to inform the risk assessment process.
There are multiple reasons to increase the efficiency in the risk assessment process and incorporate modern technology in evaluating the potential health effects of chemicals. First, chemicals without published risk assessment values are not considered quantitatively in the overall hazard index calculation when evaluating contaminated sites where multiple chemicals exist (EPA, 1989) . Therefore, these chemicals are treated as not posing any hazard leading to a potential underestimation of hazard at any given contaminated site. Second, the economic costs, time, and animal numbers required to perform the traditional toxicity tests that underlie current risk assessments limit the number of chemicals that can be evaluated (NRC, 2007b) . The resulting studies cannot keep pace with the number of chemicals introduced into commerce or released into the environment (Judson et al., 2009) . These difficulties lead to a lack of data on which to base risk assessment values. Finally, the use of traditional high-dose animal studies and a simple linear extrapolation to environmental doses does not incorporate potential dose-dependent changes in mechanism that occur for many chemicals (Slikker et al., 2004) . This may reduce the biological relevance of the endpoints used in the risk assessment.
The use of genomic technology in toxicology began more than a decade ago (Nuwaysir et al., 1999) . Since that time, the technology has moved away from a specialized laboratory technique to an off-the-shelf commodity. Advances in microarray technology now include the capability to survey the entire transcriptome (Bertone et al., 2004; Kwan et al., 2008; Xing et al., 2007) providing a global evaluation of cellular changes. The technology has also become more reliable and reproducible. Small changes in gene expression can now be reliably detected with detection thresholds around 1 PM. (Abdueva et al., 2007; Shi et al., 2006; Shippy et al., 2006) , and extensive validation studies performed by the MicroArray Quality Control project demonstrated consistent results across multiple platforms and research sites (Shi et al., 2006) . As a result of these advances, the transcriptional changes resulting from chemical exposure may be comprehensively evaluated and interpreted.
The use of genomic technology in chemical risk assessment has been widely discussed (NRC, 2007a) , but few examples exist demonstrating its practical application. The primary advantages in applying genomic technology to risk assessment are the sensitivity and comprehensive examination of the molecular changes resulting from chemical exposure. These molecular changes include both the direct and indirect effects of the chemical on the cell or tissue. The direct effects include potential key events in the mode of action for a chemical, whereas the indirect effects include secondary processes that are activated following the initial damage. In either case, it could be argued that toxicity would not occur without alterations in the transcriptional program (Farr and Dunn, 1999) . When performed in dose-response, gene expression microarray analysis can provide both quantitative and qualitative information on the dose at which cellular processes are affected and the underlying biology of dose-dependent transitions. This information can then be used to identify a transcriptional point of departure for chemical risk assessment (Thomas et al., 2007a) .
In the present study, female B6C3F1 mice were exposed to multiple concentrations of five chemicals that were positive for lung and/or liver tumor formation in a 2-year rodent cancer bioassay. The mice were exposed for a period of 13 weeks, and the target tissues were analyzed for traditional histological and organ weight changes and transcriptional changes using microarrays. The dose-response changes in gene expression were analyzed using a benchmark dose (BMD) approach and the responses grouped based on cellular biological processes (Thomas et al., 2007a) . The transcriptional points of departure for the five chemicals were compared with both noncancer and cancer points of departure based on apical endpoints. In this paper, the term apical endpoints refers to the traditional toxicology endpoints such as histological or organ weight changes for noncancer effects and tumor formation for cancer effects. The results demonstrate that transcriptomic changes following a 13-week exposure provided potential estimates of noncancer and cancer points of departure for use in quantitative risk assessments. Animals and treatment. The animal exposures for NPTH and MECL have been described previously (Thomas et al., 2009) . Female B6C3F1 mice were obtained from Charles River Laboratories (Raleigh, NC). All five of the chemicals used in this study have been previously tested by the National Toxicology Program (NTP) in a 2-year rodent cancer bioassay (NTP, 1986 (NTP, , 1987 (NTP, , 1992 (NTP, , 1993 (NTP, , 2004 . Animals were exposed for a total of 13 weeks in a five-point dose-response (Table 1) . A matched vehicle control was run concurrently with the exposure. The concentrations for these exposures overlapped those in the original NTP rodent bioassay.
MATERIALS AND METHODS
Mice were housed in a temperature-(17.8°C-26.1°C) and humidity (30-70%)-controlled environment with a standard 12-h light/dark cycle. Airflow within the housing environment was maintained at 12-15 air changes per hour. The animals were provided access to water purified by reverse osmosis and certified, ground NIH-07 food (Zeigler Brothers Inc., Gardners, PA) ad libitum except for animals exposed via inhalation where food and water were withheld during exposures. At the beginning of each study, the mice were randomized by weight and divided into treatment groups. Animal treatment was initiated at 5-6 weeks of age and were performed via the route and dose listed in Table 1 . For gavage exposures, mice were housed five per cage in polycarbonate cages. Gavage exposures were administered 5 days per week. For inhalation exposures, mice exposed 6 h/day, 5 days/week in either 1-m 3 whole-body inhalation chambers (Hazelton H1000, Lab Products, Seaford, DE) or singleanimal whole-body chambers (Wong et al., 2008) . For animals exposed in the 1-m 3 whole-body inhalation chambers, animals were also housed individually in the chamber during nonexposure periods. For animals exposed in the singleanimal whole-body chambers, animals were placed into the chambers prior to the start of exposure and then removed from the chambers and returned to domiciliary housing (five animals per cage) after the end of the 6-h exposure.
Animal use in this study was approved by the Institutional Animal Use and Care Committee of The Hamner Institutes for Health Sciences and was conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. Animals were housed in fully accredited American Association for Accreditation of Laboratory Animal Care facilities.
Necropsy and histology. Following 13 weeks of exposure, the mice were euthanized with a lethal ip dose of sodium pentobarbital (Abbott Laboratories, Chicago, IL). The four right lung lobes were isolated by suturing, removed, and minced together in RNAlater (Ambion, Austin, TX). The left lung lobe was inflated with 10% neutral buffered formalin. The formalin-fixed lung samples were embedded into paraffin blocks, sectioned at 5 lm, and stained with hematoxylin and eosin. The right, caudate, and median liver lobes were TRANSCRIPTOMIC-BASED RISK ASSESSMENT removed and minced together in RNAlater (Ambion). A section of the left liver lobe was embedded in a paraffin block, sectioned at 5 lm, and stained with hematoxylin and eosin. Histological changes were assessed by an accredited pathologist.
Gene expression microarray measurements. Microarray measurements were performed on four to five animals per treatment group and five animals in the concurrent vehicle control group. Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). The isolated RNA was further purified using RNeasy columns (Qiagen, Valencia, CA), and the integrity of the RNA was verified spectrophotometrically and with the Agilent 2100 Bioanalyzer (Palo Alto, CA). Double-stranded complementay DNA (cDNA) was synthesized from 5 lg of total RNA using the One-Cycle cDNA synthesis kit (Affymetrix, Santa Clara, CA). Biotin-labeled complementary RNA (cRNA) was transcribed from the cDNA using the GeneChip IVT Labeling Kit (Affymetrix). Fifteen micrograms of labeled cRNA was fragmented and hybridized to Affymetrix Mouse Genome 430 2.0 arrays for 16 h at 45°C. The hybridized arrays were washed using the GeneChip Fluidics Station 450 and scanned using a GeneChip 3000 scanner. The gene expression results have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (accession no.: GSE18858 and GSE17933).
Transcriptional BMD analysis. The analysis of the gene expression microarray data was performed as described previously (Thomas et al., 2007a) with modification. The microarray data were processed using robust multiarray average normalization with a log 2 transformation (Irizarry et al., 2003) . All probe sets were fit as continuous data to a series of four different dose-response models-linear, 2°polynomial, 3°polynomial, and power models. Each model was run assuming constant variance, and the benchmark response (BMR) factor was set to 1.349 multiplied by the SD in the control animals to estimate a BMD with a 10% increase in tail area (for details on its derivation, see Thomas et al., 2007a) . For model selection, a nested likelihood ratio test was performed on the linear, 2°polynomial, and 3°polynomial models. If the more complex model provided a significantly improved fit (p < 0.05), the more complex model was selected. If the more complex model did not provide a significantly improved fit (p ! 0.05), the simpler model was selected (Posada and Buckley, 2004) . The Akaike information criterion (AIC) for the selected polynomial model was then compared with the AIC for the power model. The model with the lowest AIC (Akaike, 1973) was selected as the final model and was used to calculate a BMD and a benchmark dose lower confidence bound (BMDL). To avoid model extrapolation and any potential bias from poor fitting genes, probe sets with a BMD value greater than the highest dose or a goodness-of-fit p value < 0.05 were removed from further analysis.
Gene ontology analysis and calculation of summary values. The gene annotations and gene ontology (GO) classifications for all probe sets on the Affymetrix Mouse Genome 430 2.0 array were downloaded from the Affymetrix Web site. Affymetrix probe sets that had a BMD less than the highest dose and a goodness-of-fit p value > 0.05 were converted into unique genes based on their NCBI Entrez Gene ID. When two or more probe sets were associated with a single gene, the BMD and BMDL values for the individual probe sets were averaged to obtain a single BMD and BMDL value. The Entrez Gene identifiers were then matched to their corresponding biological process GO categories. GO categories with < 5 genes were removed from the analysis. Unless otherwise stated, median BMD and BMDL values were used to summarize each GO category.
BMD analysis of noncancer endpoints. The relative liver weight data for DCBZ, PGBE, TCPN, and MECL were fit as continuous data to a series of seven models (exponential model 2, exponential model 3, exponential model 4, exponential model 5, linear, 2°polynomial , and power) (BMDS software, Version 2.1.1, U.S. EPA). The model with the lowest AIC was selected, and the default BMR of 1 SD was used to estimate the BMD and BMDL.
The treatment-related histopathological changes were fit as dichotomous data to a series of eight models (gamma, logistic, log logistic, probit, log probit, multistage with a 2°polynomial, Weibull, and quantal-linear) (BMDS software, Version 2.1.1, U.S. EPA). Because concurrent vehicle control animals were run with each chemical, the incidence for each lesion was combined across all control to provide a better estimate of the background rate. The model with the lowest AIC was selected. A default BMR of 10% extra risk was used to estimate the BMD and BMDL. All goodness-of-fit assessments were evaluated by a likelihood ratio-based p value (compared with the saturated model).
BMD analysis of cancer endpoints. The combined adenoma and carcinoma in the lung (NPTH and MECL) and combined adenoma and carcinoma in the liver (DCBZ, MECL, TCPN, and PGBE) from the 2-year rodent cancer bioassays were fit to the multistage cancer model with a BMR of 10% extra risk (BMDS software, Version 2.1.1, U.S. EPA). A secondorder polynomial was selected as the best model for all the data sets with the exception of the lung tumor response for MECL, for which a first-order polynomial was selected as the best model. Goodness-of-fit was assessed by a likelihood ratio-based p value (compared with the saturated model).
Partial correlation analysis. Prior to performing the partial correlation analysis, the BMD and maximum tolerated dose (MTD) values for chemicals exposed via inhalation were adjusted to a common mg/kg-day scale. The adjustment was performed by multiplying the BMD and MTD values (in mg/m 3 ) by 0.526 m 3 /kg-day, which is based on a mean minute ventilation rate of 1.46 ml/g body weight for adult mice (Fairchild, 1972) and a 6 h/day exposure. The adjustment had only minor effects on the value of the partial correlation coefficients but was done to avoid potential leveraging effects when data values exist on multiple scales. The calculation of the partial correlation coefficients was performed both in JMP (Version 8.0.1, SAS Institute Inc., Cary, NC) and using customized Perl scripts based on standard methods (Steel and Torrie, 1980) . The statistical significance of the partial correlation coefficients was assessed using a standard t distribution (Steel and Torrie, 1980) . Human exposures. Although the NTP rodent cancer bioassay was performed using the oral route, human exposure to DCBZ is predominantly through inhalation (ATSDR, 2006) . The average adult daily intake for DCBZ from ambient air was estimated at 0.5 lg/kg-day (ATSDR, 2006). For TCPN, little information exists to evaluate exposure to the chemical for the general population (ATSDR, 1992) . In California, ground water concentrations ranged from 0.1 to 5 ppb (NTP, 1993) . Using the maximum observed concentration of 5 ppb and a drinking water consumption of 3.5 l/day for a 70-kg male, the human exposure was estimated to be 0.25 lg/kg-day. For MECL, the average daily dose from ambient air ranged from 33 to 309 lg/day and a daily air intake of 23 m 3 by an adult (ATSDR, 2000) . The highest daily exposure concentration for MECL was used in the analysis (13 lg/m 3 ). For NPTH, the average human exposure was estimated to be 0.95 lg/m 3 (ATSDR, 2005) .
RESULTS

Organ Weight and Histological Changes
Treatment with each of the liver carcinogens produced increased relative liver weights in at least one dose (Fig. 1) . DCBZ increased the relative liver weights at four of the five doses, whereas TCPN increase relative liver weights at only the highest dose. PGBE and MECL increased relative liver weights at the highest three doses. The changes in absolute liver weights are provided in Supplementary figure 1.
Although gene expression analysis was performed only on the target tissue determined by the NTP rodent cancer bioassay (Table 1) , histological analysis was performed in both the liver and the lung for all chemicals. In mice exposed to NPTH via inhalation, treatment-related changes in the liver were only observed at the 157.3 mg/m 3 concentration with 8 out of 10 196 mice showing centrilobular hypertrophy. In the lungs, NPTH caused a concentration-dependent increase in bronchiole epithelial degeneration. The incidence of bronchiole epithelial degeneration was 1/5, 0/10, 1/10, 7/10, 10/10, and 10/10 at the 0, 2.6, 15.7, 52.4, 104.9, and 157.3 mg/m 3 NPTH concentrations, respectively. The severity was minimal in the 52.4 mg/m 3 exposure group and transitioned to mild in the 104.9 and 157.3 mg/m 3 groups. In the livers of mice exposed to MECL via inhalation, concentration-related changes in periportal vacuolation were observed. The vacuolation was characterized by variably sized vacuoles within the cytoplasm of hepatocytes that frequently displaced the nuclei. The finding was more pronounced in the periportal areas, but not limited to them. The incidence of periportal vacuolation was 0/5, 0/10, 0/10, 9/10, 10/10, and 8/10 at the 0, 347, 1737, 6948, 10,422, and 13,896 mg/m 3 MECL concentrations, respectively. No treatment-related histological changes were observed in the lungs of MECLexposed mice.
In mice exposed to PGBE via inhalation, treatment-related histological changes in the liver were only observed at the 6488 mg/m 3 concentration with 7 of 10 mice showing centrilobular hypertrophy. No treatment-related histological changes were observed in the lungs of PGBE-exposed mice.
In mice exposed to TCPN via gavage, no treatment-related histological changes were observed in the liver. In the lungs, TCPN caused bronchiole degeneration characterized by changes in the terminal bronchioles including large or irregular BMD and BMDL for chemicals administered by inhalation adjusted to common mg/kg-d scale based on respiration rate and volume and a 6 h/day exposure.
TRANSCRIPTOMIC-BASED RISK ASSESSMENT nuclei, pyknosis, and eosinophilic cytoplasm with occasional flattening of the epithelium. The incidence of bronchiole degeneration was 0/5, 0/10, 0/10, 0/10, 7/10, and 8/9 at the 0, 2, 6, 20, 40, and 60 mg/kg-day TCPN doses, respectively. The effect was graded as minimal. In mice exposed to DCBZ via gavage, treatment-related centrilobular hypertrophy was observed in the liver. The incidence of centrilobular hypertrophy was 0/4, 0/9, 0/9, 8/8, 8/ 9, and 9/9 at the 0, 100, 300, 400, 500, and 600 mg/kg-day DCBZ doses, respectively. The effect was graded as minimal. No treatment-related histological changes were observed in the lungs of DCBZ-exposed mice.
BMD Analysis of Noncancer Endpoints
The changes in relative liver weight and histological changes in this study were used to obtain BMD values for noncancer effects in the target tissues. For the changes in relative liver weight, the statistical models appeared to adequately describe the dose-response behavior for most chemicals (goodness-of-fit p > 0.1) with the exception of MECL ( Table 2 ). The nonmonotonic behavior of the dose-response for MECL resulted in a marginal fit for all models with the linear model producing the lowest AIC value. For the histological changes, the statistical models adequately described the dose-response behavior for all chemicals (goodness-of-fit p > 0.1; Table 3 ).
BMD Analysis of Cancer Endpoints
The combined adenoma and carcinoma incidence in the lung (NPTH and MECL) (NTP, 1986 (NTP, , 1992 and the combined adenoma and carcinoma incidence in the liver (DCBZ, MECL, TCPN, and PGBE) (NTP, 1986 (NTP, , 1987 (NTP, , 1993 (NTP, , 2004 were analyzed to obtain the BMD values corresponding to 10% extra risk (Table 4 ). In the original bioassays, DCBZ, MECL, and NPTH were run with two doses and a control, whereas TCPN and PGBE were run with three doses and a control. For DCBZ, the nonmonotonic response and the limited number of doses in the original bioassay resulted in an inadequate fit to the model (p ¼ 0.004). Nonetheless, the second-order multistage cancer 
BMD Analysis for Transcriptional Changes
The BMD values for each gene were grouped based on GO biological processes and summarized as the median of each GO category. In this study, the median BMD values for the GO categories will be referred to as transcriptional BMD values to distinguish them from the BMD values for tumor incidence, organ weight changes, and pathological effects. A comparison of the distribution of transcriptional BMD values provides an indication of where in the dose-response curve the majority of biological processes become transcriptionally active. The distribution of transcriptional BMD values was dramatically different across the chemicals and tissues (Fig. 2, left side) . For MECL in the lung, PGBE, and DCBZ, the GO category BMD values were lognormally distributed. The distributions for MECL in the liver, NPTH, and TCPN were less skewed and conformed to either a Weibull or a normal distribution. When analyzed as a cumulative probability function, no consistent percentage of transcriptionally active GO categories was identified at the BMD values for the cancer or noncancer apical endpoints (Fig. 2, right side) .
The most sensitive GO categories for each chemical were identified (Table 5 ) and both the BMD and the BMDL values were compared with the corresponding values for the cancer and noncancer apical endpoints (Fig. 3) . The transcriptional BMD and BMDL values were generally less than or similar to the corresponding values for the apical endpoints. The one exception was for MECL in the lung where the BMD value for tumor incidence (790.7 mg/m 3 ) was less than the most sensitive transcriptional BMD value (1137.1 mg/m 3 ).
Comparison of Transcriptional and Noncancer BMDs for Noncancer Risk Assessment
A direct analysis of the relationship between transcriptional and noncancer BMD values is likely to be confounded by the correlation between the potency of the chemicals to induce noncancer endpoints and the MTD. This correlation has been demonstrated for cancer endpoints (Krewski et al., 1993; Razzaghi and Gaylor, 1996) . In this study, the correlation between the MTD and the BMD for the lowest noncancer apical endpoint was statistically significant (r ¼ 0.911, p ¼ 0.031). To account for this potential confounding, partial correlation coefficients were calculated between the transcriptional BMD values for the different GO categories and the BMD values for the lowest noncancer endpoint when adjusted for the MTD. The unadjusted correlation coefficients were also calculated for comparison. The results identified GO categories that were highly positively correlated with the noncancer BMD values (Table 6 ). The GO category related to the acute inflammatory response had the highest partial correlation coefficient (r ¼ 1.000). GO categories related to immune response, protein maturation, and phosphorylation were also prevalent among those with the highest positive correlation. GO categories with related functions may share significant overlap in genes leading to some redundancy among those categories with a high partial correlation. Nonetheless, the results suggest that the median transcriptional BMD values for the immune response, protein TRANSCRIPTOMIC-BASED RISK ASSESSMENT maturation, and phosphorylation GO categories following a 13-week exposure and BMD values for noncancer endpoints are highly correlated with and without adjustment for the MTD.
For chemicals where human exposure has been measured or estimated, another method for assessing noncancer risks is through a margin of exposure approach. The transcriptional BMDL values were adjusted for continuous exposure and then compared with human exposure estimates to obtain a margin of exposure (Table 7) . For the four chemicals with human exposure estimates, the margin of exposure based on the transcriptional BMDL as the point of departure ranged from 1900 to 54,000, suggesting that they provide a conservative point of departure for a margin of exposure approach to risk assessment.
Comparison of Transcriptional and Tumor Incidence BMDs for Cancer Risk Assessment
As highlighted in the analysis of noncancer endpoints, a direct analysis of the relationship between transcriptional and tumor incidence BMD values is confounded by the correlation between carcinogenic potency and the MTD (Krewski et al., 1993; Razzaghi and Gaylor, 1996) . In this study, the correlation between the MTD and the BMD for tumor incidence was not statistically significant (r ¼ 0.731, p ¼ 0.099). However, the MTD and BMD values for the MECL lung tumor endpoint were considerably different, thereby lowering the overall correlation. When the MECL lung tumor endpoint was excluded, the results were highly significant (r ¼ 0.998, p < 0.001). To account for potential confounding, partial correlation coefficients were calculated between the transcriptional BMD values for the different GO categories and the BMD values for tumor incidence when adjusted for the MTD. The unadjusted correlation coefficients were also calculated for comparison. Similar to the noncancer analysis, the results identified GO categories that were highly positively correlated with the carcinogenic potency and GO categories (Table 8 ). The GO category related to the Jun N-terminal kinase (JNK) signaling pathway had the highest partial correlation coefficient (r ¼ 0.9987). Other GO categories traditionally associated with the carcinogenic process also showed a positive correlation with tumor incidence. The results suggest that the median transcriptional BMD values for these categories following a 13-week exposure and BMD values for tumor incidence are highly correlated with and without adjustment for the MTD. A total of 28 GO categories showed a significant partial correlation coefficient for both cancer and noncancer endpoints (Table 9 ). This suggests that a relatively small subset of genes contained in these GO categories may potentially be used to estimate both cancer and noncancer BMD values.
DISCUSSION
There has been considerable debate on whether genomic data can be used to fill critical data gaps in a chemical risk assessment. Although much of the discussion has centered on the use of genomic data to inform mode of action, the results of this study demonstrate that transcriptomic studies may be practically applied within a non-mode of action framework. The degree of correlation between the transcriptional BMD values and those for the traditional apical endpoints suggests that they may be used as potential surrogates for both cancer and noncancer points of departure. Notably, the lack of histological changes in the lung for MECL in our study suggests that cancer-related points of departure cannot be Transcrptional BMDL for most sensitive GO category adjusted for continuous exposure (6/24 h, 5/7 days).
TRANSCRIPTOMIC-BASED RISK ASSESSMENT accurately estimated from subchronic histological endpoints alone. The use of genome-wide transcriptomic data provides a more comprehensive view of cellular responses than that provided by light microscopy resulting in a more robust basis for assessing risk associated with chemical exposure.
The present study provided an initial estimate of the correlation between transcriptional and apical points of departure. However, the current selection of five chemicals covered a limited array of potential mechanisms and structural classes. Both the correlation and the selection of informative GO categories may change when more chemicals are examined. In addition to a limited range of chemical diversity, the present study included a limited selection of tissue targets. Given the potential differences in the relative percentage of target cells, it is possible that the correlation between transcriptional BMD values and those for the apical endpoints is not uniform across tissues and organs.
The inclusion of MECL in the study allowed the comparison between transcriptional and tumor incidence BMD values across tissues with large differences in potency. In the lung, the BMD value for tumor incidence was estimated at 790.7 mg/m 3 , whereas in the liver, the BMD value was 3544.6 mg/m 3 . Although the tissue-related difference in the transcriptional BMD value for the most sensitive GO category was minimal, the overall distributions of transcriptional BMD values was highly different (Fig. 2) . The differences in the distributions may be because of either the route of administration or tissue sensitivity. Assuming that the relevant route of administration is included in the design, tissue-specific profiles may also be required to accurately estimate the critical points of departure for each chemical. From a biological perspective, the collection of gene expression profiles across multiple tissues would provide comprehensive and robust estimates for points of departure in a chemical risk assessment.
In developing a comprehensive and practical approach for applying transcriptomic data to risk assessment, 13-week doseresponse studies could be performed on untested, priority chemicals (Fig. 4) . A battery of eight tissues could be collected that include those most frequently positive in rodent cancer bioassays (liver, lung, mammary gland, stomach, vascular system, kidney, hematopoietic system, and urinary bladder). In a previous analysis, these eight tissues cover 92 and 82% of all mouse and rat carcinogens, respectively (Gold et al., 2001) . Additional tissues would need to be added for neurological, developmental, and reproductive effects, which could include brain, the developing fetus, and gonadal tissue. Gene expression microarray analysis on these tissues would allow the estimation of transcriptional BMD and BMDL values for key noncancer and cancer processes (i.e., GO categories) in each of the tissues. In parallel, the gene expression profiles in each tissue would be analyzed using statistical classification models to predict the carcinogenic activity of the chemical. Previous studies in the mouse lung and rat liver have demonstrated the feasibility of the classifying the carcinogenic activity of a chemical based on the gene expression profile (Fielden et al., 2007; Thomas et al., 2007b Thomas et al., , 2009 . Additional sets of transcriptional biomarkers could be identified for the remaining tissues in future studies. For all chemicals, the lowest transcriptional BMD values (and associated BMDL) across the battery of tissues among the most highly correlated, noncancer-related GO categories could then be used to estimate noncancer reference doses (RfD). For the predicted carcinogens, the lowest transcriptional BMD values (and associated BMDL) across the tissues among the most highly correlated, 202 cancer-related GO categories could be used as the point of departure in a cancer risk assessment. The transcriptionally derived RfD and slope factors could serve as a basis for a risk assessment, and as the need arises, these risk assessment values could be updated or replaced as newer or more complete studies are performed. The identification of these key processes would require additional studies using prototype chemicals that are known to cause effects in each of the tissues with the adverse endpoints. Until these studies are performed, an interim alternative could be to use the GO category with the lowest transcriptional BMD across all analyzed tissues to estimate a noncancer point of departure for an RfD. Although the most sensitive transcriptional response might not necessarily indicate biological significance related to an adverse effect, basing the point of departure on the most sensitive transcriptional response would be conservative until the transcriptional changes related to the adverse effects are understood. Regardless of the approach, the establishment of provisional noncancer and cancer values using transcriptomic studies could substantially reduce the economic and animal costs associated with performing a risk assessment on a per chemical basis and increase the number of published assessments. The increase in published risk assessments would provide interim guidance for chemicals that have not been previously evaluated while also basing decisions on the best available biological knowledge of the chemical effects.
Although this study provides a practical approach for using genomic technology in chemical risk assessments, the long-term goal is to use the rich biological information contained in these genomic studies to identify the mode of action for chemical and use the corresponding GO categories to define relevant points of departure for cancer and noncancer endpoints. From a biological perspective, the transcriptional dose-response data contain information of mechanistic significance that is mixed together with confounding secondary transcriptional changes not directly related to the key events. In this study, the transcriptional measurements were performed only at the 13-week time point and do not contain information regarding temporality in key events. Future studies focused on mode of action will need to incorporate time course changes in expression. Apart from time course information, establishing a mechanistic relationship between the BMD values for the different GO categories and the apical endpoints will require sets of prototypical chemicals with known mechanisms. Few chemicals exist with extensive
